Cell and gene based therapies are the next frontier in medicine. Unlike other therapies they have the potential to cure diseases as opposed to merely treating the disease, as is the case with more traditional treatment modalities. It feels like they almost belong in a sci-fi movie; genetically engineering a patient’s own cells or replacing
In this update, we’re digging into UK venture capital conditions and their impact, shedding light on crucial factors influencing EIS fund performance. We’ll also dive into why Mercia EIS is still holding up compared to the rest of the market and how our conservative valuation policy shields investors from significant adjustments to Net Asset Value
Managing Director of Mercia Ventures, Peter Dines, speaks to Wealth Club about the portfolio, recent investments, the Northern VCT investment approach, and the challenges and opportunities in the current economic climate. Recorded October 2023 with Wealth Club.
Mercia Ventures first invested in Naitive’s seed round back in 2021. Naitive are seeking to redefine how bone diseases are diagnosed and managed, starting with one of the most prominent chronic diseases – Osteoporosis. The team have largely operated in the shadows to date, but following a string of significant product and commercial milestones, it
Earlier this year Mercia Ventures’ Lee Lindley and Marina Fuentes led a $10m investment into Camena Bioscience from Mercia Ventures. Camena have developed a ground-breaking, proprietary DNA synthesis platform which we think will revolutionise the synthetic DNA market, helping to catalyse the development and advancement of precision medicines for patients worldwide. Read about why Mercia
Mercia’s FY24Interim Results presentation, presented by Dr Mark Payton, Chief Executive Officer, Martin Glanfield, Chief Financial Officer and Julian Viggars, Chief Investment Officer. Visit Mercia’s EIS area
Mercia Asset Management PLC is pleased to announce its interim results for the six months ended 30 September 2023. Mark Payton, Chief Executive Officer of Mercia, commented: “Mercia has never been financially stronger. The first six months of FY24 have witnessed record revenues derived predominantly from Mercia’s profitable and cash generative third-party fund management operations.
Mercia Asset Management PLC today announces that it is commencing a share buyback programme of up to £5.0million. The Share Buyback Programme will be for on market purchases of up to £5.0million worth of Ordinary shares in the Company (the “Maximum Monetary Amount”) in accordance with certain pre-set parameters (the “Share Buyback”). The Share Buyback
Join Dr Paul Mattick for a 30 minute, high-level and informative briefing where he provides insightful reactions and a comprehensive briefing on the key announcements from the Chancellor’s Autumn Statement. Visit Mercia’s EIS area
Mercia announced the profitable sale of nDreams to Aonic for an enterprise value of £90.3million. CEO, Dr Mark Payton spoke to Tom Warner of Proactive to detail more about the exponential growth of one of the leading VR studios in the world, and explains Mercia’s role as a supportive investor in the UK’s startup landscape.